Mission

At Sharlin Health Neuroscience Research Center, we recognize that neurological diseases are becoming a growing epidemic. Our Springfield functional medicine doctors strive to discover and provide new, integrative treatments, and technology to restore and regenerate every patient’s health and life.

Research is to see what everyone else has seen, and think what no one else has thought.

– Albert Szent-Györgyi

Clinical Research Team

Dr. Sharlin

Principal Investigator

Ken Sharlin, M.D., M.P.H., IFMCP, is a board-certified neurologist, consultant, functional medicine practitioner, Assistant Clinical Professor, researcher, author, and speaker. His medical degrees are from Emory University, The University of Virginia, and Vanderbilt University. His functional medicine certification is through The Institute for Functional Medicine. He is author of the #1 best-seller The Healthy Brain Toolbox: Neurologist-Proven Strategies to Improve Memory Loss and Protect Your Aging Brain. His most recent publication, Reversal of Cognitive Decline: 100 Patients, can be found in the peer-reviewed Journal of Alzheimer’s & Parkinsonism, and he has been the primary investigator in several pharma-sponsored clinical trials that have helped bring new therapeutics to market. Dr. Sharlin practices general neurology, and directs his functional medicine program, Brain Tune Up!, in Ozark, MO.

Shawna Tindall

Clinical Research Manager

Shawna has over 11 years of experience in the nursing field in areas such as family medicine, ob/gyn, med-surgical medicine, cardiology, home health, and has been in Clinical Research for the last 4 years. She obtained her Bachelor’s Degree from Southwest Missouri State University. She obtained her Associate’s Degree in nursing from Keiser University. She also holds certifications in Advanced IV Therapy and Phlebotomy Techniques, Research, and Medical Assisting and is a certified MoCA and CDR rater along with many other diagnostic rating scales. Shawna is currently going back to school to complete her nurse practitioner studies.

Mikhayla Hamilton

Clinical Research Assistant

Mikhayla Hamilton is a clinical research assistant, and is currently finishing her bachelor of science in psychology, and will then begin a program to receive her doctorate in neuropsychology. Her specific areas of interest include traumatic brain injuries, multiple sclerosis, and mirror neurons. She is a Nationally Registered Certified Phlebotomy Technician with certifications in IV therapy and advanced phlebotomy techniques. She has several other certifications, including in dementia rating, the neuropsychiatric inventory questionnaire, and in co-occurring disorders.

Study Patient Testimonials

“I was diagnosed with MS in 2004 and was so tired of the medications that I was prescribed. Having to do a shot every other day is bad enough, but knowing that I was going to feel sick every other day was worse. And, I never felt better. I felt level, but when level wasn’t great, that just isn’t great overall. I joined the Clinical Trial for Ofatumumab in September of 2018. I thank God for giving people the knowledge to make a medication that actually improves this horrible disease. My MRIs were improved every time. I went from having over 20 lesions to less than 10. I have so much more energy and feel more ‘normal’ than I have in years. “

– Angela

Information Form

Why Participate in Springfield Functional Medicine Clinical Trials:

The Need that Inspires Our Research

  • Neurological diseases impact an estimated 100 million people every year, according to the American Neurological Association.
  • In 2015, a study found that Neurological diseases are the largest cause of disability worldwide.
  • As of 2014, a study of the 9 most common neurological diseases in the US revealed the overall cost is about $789 billion.

Safety in Clinical Research

Potential Risks

  • It may cause side effects or may not work for you.
  • You may not get the new experimental treatment.

How You Are Protected

  • Frequent visits to monitor symptoms and side effects.
  • Careful study plan, or protocol, that describes exactly what will happen in the study.
  • You will have an Informed Consent which tells you exactly what to expect in the study. A clinical trial team member will  go over each page of the consent and answer any questions you or your family members might have. You will be asked to sign this consent and the Principal Investigator will sign as well and you will receive a copy. Signing the Informed Consent just indicates you understand the details and want to participate in the study. You may revoke this consent at any time for any reason.
  • An Institutional Review Board is made up of doctors, scientists, and lay people like yourself, and they make sure every study in the United States does not expose the participants to any unnecessary risks.
  • The Data and Safety Monitoring Committee is made up of experts in your condition, and they monitor the results of the study throughout. If it is harmful or not effective, they stop the study immediately.

Benefits

  • The treatments are free.
  • The access to the medical care in regards to the condition covered in the trial are free, with few exceptions.
  • Participants are often paid for their participation.

Clinical Trials

Past:

COMB157G2301

  • A Multiple Sclerosis study for a Disease Modifying Therapy.
  • A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis.

COMB157G2102

  • A Multiple Sclerosis study for a Disease Modifying Therapy.
  • A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients.

CFTY720DUS40

  • A Multiple Sclerosis study for a Disease Modifying Therapy.
  • A 12-Month, prospective, multicenter, two-cohort, nonrandomized, open-label study in adult patients with Relapsing Multiple Sclerosis (RMS), to investigate changes in immune phenotype biomarkers after treatment with 0.5mg fingolimod (FTY720).

Tenant Clinical Study

  • A device study for improving the healing process in chronic wounds.
  • Microcurrent as an adjunct therapy in wound healing and reducing pain in patients with chronic wounds.

MDA702-PD

  • A retrospective observational study on Parkinson’s disease patients with motor fluctuations.

Current:

COMB157G2399

  • An extension Multiple Sclerosis study for a Disease Modifying Therapy.
  • An open-label, single arm, multi-center extension study evaluation long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis.

Protocol 4800

  • A single or multiple visit protocol for collection of DNA/RNA/SERUM/PLASMA/CSF in Amyotrophic Lateral Sclerosis and related disorders.

EFC16035

  • A Multiple Sclerosis study for a Disease Modifying Therapy.
  • Phase 3, Randomized, Double-Blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Primary Progressive Multiple Sclerosis.

17-AVP-786-205

  • Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in patients with traumatic brain injury (TBI).

COMB157G2399 Vaccination Sub-Study

  • A sub-study to evaluate the effects of ofatumumab subcutaneous treatment on the immune responses following vaccination in patients with relapsing forms of multiple sclerosis.
0